Merck & Co Inc MRK
News
Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
Merck Raises Quarterly Dividend by 3.5%
Merck Announces First-Quarter 2027 Dividend
Merck Gains Support for Broader Use of Preventive RSV Treatment
The science of vaccines is rapidly advancing - despite the anti-vax movement
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
Merck to Participate in the Jefferies Global Healthcare Conference in London
Merck Says Investigational MASH Drug Shows Promise in Midstage Trial
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
Moderna Swings to 3Q Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes — Update
Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
The big winners of the tech wreck are biopharma stocks
Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline
Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 1.76% Stock Decline
Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock closed at a record high.


